Local Drug Delivery of ONO-4007 Inhibits Neointimal Hyperplasia in Dogs.

ONO-4007 的局部给药可抑制狗的新内膜增生。

基本信息

  • 批准号:
    10670680
  • 负责人:
  • 金额:
    $ 1.98万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1998
  • 资助国家:
    日本
  • 起止时间:
    1998 至 2000
  • 项目状态:
    已结题

项目摘要

ONO-4007 is a potent antineoplastic drug, which induces apoptosis in neoplastic cell. The aim of this study was whether facilitation of apoptosis in neointima after vascular injury could inhibit restenosis process by local ONO-4007 delivery. Methods : In eight dogs(13.2±2.2kg)bilateral femoral arteries were injured by three times 30 sec balloon inflation of PTCA catheter, which balloon size was 1.3〜1.5 times as large as the artery. In one side, ONO-4007(0.05mg or 0.5mg, n=4 in each group)was delivered by a microporous infusion catheter. In the other side saline was delivered as a control. Two or four weeks after balloon injury, the femoral arteries were resected and prepared for histological examination. Results : Total vassel area(VA)and medial area/VA did not differ between the groups. At four weeks, the intimal area/VA was significantly reduced in 0.5mg sites(2.75±1.06%)compared with the control sites(6.42±3.42%). Maximum neointimal thickness were significantly thinner in the treatment sites(0.05mg group, 65.5±64.4μm ; 0.5mg group, 50.5±21.7μm)than that in the control sites(128±104μm). At two weeks, Tunnel positive cells rate in the neointima were significantly increased in the treatment sites(71.4±14.1% vs 12.9±5.3%). Conclusion : These data indicate facilitation of apoptosis in the injured vassel by local ONO-4007 delivery inhibits neointimal hyperplasia in dog's femoral artery.
ONO-4007是一种有效的抗肿瘤药物,可诱导肿瘤细胞凋亡。本研究的目的是探讨ONO-4007局部给药对血管损伤后新生内膜凋亡的促进作用是否能抑制再狭窄的发生。研究方法:8只犬(13.2±2.2kg),经皮冠状动脉腔内成形术(PTCA)导管球囊扩张3次,每次30秒,球囊尺寸为动脉的1.3〜1.5倍,造成双侧股动脉损伤。在一侧,通过微孔输液导管递送ONO-4007(0.05mg或0.5mg,每组n=4)。在另一侧输送生理盐水作为对照。球囊损伤后2周或4周,切除股动脉并准备进行组织学检查。结果:总血管面积(VA)和内侧面积/VA在组间无差异。4周时,与对照部位(6.42±3.42%)相比,0.5mg部位(2.75±1.06%)的内膜面积/VA显著降低。治疗部位的最大新生内膜厚度(0.05 mg组,65.5±64.4μm ; 0.5 mg组,50.5±21.7μm)显著薄于对照部位(128±104μm)。两周时,治疗部位新生内膜中的Tunnel阳性细胞率显著增加(71.4±14.1% vs 12.9±5.3%)。结论:这些数据表明通过局部ONO-4007递送促进损伤血管中的细胞凋亡抑制了狗股动脉中的新生内膜增生。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WAKIDA Yasushi其他文献

WAKIDA Yasushi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WAKIDA Yasushi', 18)}}的其他基金

STUDY ON THE ROLE OF Na_+-H_+ EXCHANGE ON ISCHEMIA-REPERFUSION INjURY
Na_-H_交换对缺血再灌注损伤作用的研究
  • 批准号:
    07670816
  • 财政年份:
    1995
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Significance of endoscopic quantitative evaluation of small bowel stricture in patients with Crohn's disease and elucidation of restenosis factors after balloon dilatation
内镜定量评估克罗恩病患者小肠狭窄的意义及阐明球囊扩张后再狭窄因素
  • 批准号:
    23K07446
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Targeting smooth muscle cell BMAL1 as a new therapeutic strategy against restenosis
靶向平滑肌细胞 BMAL1 作为抗再狭窄的新治疗策略
  • 批准号:
    10561398
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
Development of a multi-modal targeted nanotherapeutic to prevent restenosis in an atherosclerotic environment
开发多模式靶向纳米治疗药物以预防动脉粥样硬化环境中的再狭窄
  • 批准号:
    10667411
  • 财政年份:
    2022
  • 资助金额:
    $ 1.98万
  • 项目类别:
Development of a multi-modal targeted nanotherapeutic to prevent restenosis in an atherosclerotic environment
开发多模式靶向纳米治疗药物以预防动脉粥样硬化环境中的再狭窄
  • 批准号:
    10364365
  • 财政年份:
    2022
  • 资助金额:
    $ 1.98万
  • 项目类别:
Targeting the Meta-organismal Butyrate Pathway to Prevent Arterial Restenosis after Vascular Surgery
靶向元生物体丁酸途径预防血管手术后动脉再狭窄
  • 批准号:
    10591598
  • 财政年份:
    2021
  • 资助金额:
    $ 1.98万
  • 项目类别:
Targeting the Meta-organismal Butyrate Pathway to Prevent Arterial Restenosis after Vascular Surgery
靶向元生物体丁酸途径预防血管手术后动脉再狭窄
  • 批准号:
    10374926
  • 财政年份:
    2021
  • 资助金额:
    $ 1.98万
  • 项目类别:
Selective delivery of superoxide dismutase and catalase for restenosis prevention
选择性递送超氧化物歧化酶和过氧化氢酶以预防再狭窄
  • 批准号:
    10514528
  • 财政年份:
    2021
  • 资助金额:
    $ 1.98万
  • 项目类别:
Targeting the Meta-organismal Butyrate Pathway to Prevent Arterial Restenosis after Vascular Surgery
靶向元生物体丁酸途径预防血管手术后动脉再狭窄
  • 批准号:
    10210817
  • 财政年份:
    2021
  • 资助金额:
    $ 1.98万
  • 项目类别:
Selective delivery of superoxide dismutase and catalase for restenosis prevention
选择性递送超氧化物歧化酶和过氧化氢酶以预防再狭窄
  • 批准号:
    10315701
  • 财政年份:
    2021
  • 资助金额:
    $ 1.98万
  • 项目类别:
Machine learning techniques to predict restenosis development in superficial femoral arteries using demographic, clinical and hemodynamic descriptors
使用人口统计、临床和血流动力学描述符预测股浅动脉再狭窄发展的机器学习技术
  • 批准号:
    2436249
  • 财政年份:
    2020
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了